Join the High Cholesterol - Familial Heterozygous group to help and get support from people like you.
High Cholesterol - Familial Heterozygous News (Page 2)
Related terms: Familial Hypercholesterolemia, Heterozygous, Heterozygous Familial Hypercholesterolemia, Heterozygous FH, Hypercholesterolemia, Familial Heterozygous
FDA Approves Nexletol (bempedoic acid) to Lower LDL-Cholesterol
ANN ARBOR, Mich., Feb. 21, 2020 (GLOBE NEWSWIRE) – Esperion (NASDAQ:ESPR) announced today that the U.S. Food and Drug Administration (FDA) approved Nexletol™ (bempedoic acid) tablet, an oral, o...
FDA Approves Amgen's Repatha (evolocumab) to Prevent Heart Attack and Stroke
THOUSAND OAKS, Calif., Dec. 1, 2017 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced that following priority review of its supplemental Biologics License Application, the U.S. Food and Drug...
Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent (alirocumab) Injection
BRIDGEWATER, N.J. and TARRYTOWN, N.Y., April 25, 2017 /PRNewswire/ – Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the...
FDA Approves Repatha (evolocumab) Pushtronex - First And Only Single Monthly Injection for a PCSK9 Inhibitor
THOUSAND OAKS, Calif., July 11, 2016 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha® (evolocumab) Pushtronex™ system (o...
FDA Approves Repatha (evolocumab) to Treat Certain Patients with High Cholesterol
August 27, 2015 – The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under...
FDA Approves Praluent (alirocumab) to Treat Certain Patients with High Cholesterol
July 24, 2015 – The U.S. Food and Drug Administration today approved Praluent (alirocumab) injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein...
FDA Approves Merck’s Liptruzet (ezetimibe and atorvastatin), a New Product That Can Help Lower LDL Cholesterol
Friday, May 3, 2013 - Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Liptruzet (ezetimibe and atorvastatin)...
U.S. Food and Drug Administration Approves Crestor for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
WILMINGTON, Del., Oct. 16 /PRNewswire-FirstCall/ – AstraZeneca today announced the U.S. Food and Drug Administration (FDA) approved Crestor (rosuvastatin calcium) for use in pediatric patients ages...
Welchol (colesevelam HCl) Receives FDA Approval to Lower LDL Cholesterol in Pediatric Patients with Heterozygous Familial Hypercholesterolemia
Welchol for Oral Suspension Also Approved by FDA PARSIPPANY, N.J., Oct. 7 /PRNewswire/ – Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the...
FDA Medwatch Alert: Cholestrix
[Posted August 09, 2007] FDA warns consumers and healthcare professionals to avoid using Red Yeast Rice and Red Yeast Rice/Policosonal Complex, sold by Swanson Healthcare Products, Inc. and...
FDA Medwatch Alert: Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor)
[Posted 01/25/2008] FDA provided healthcare professionals with an early communication about an ongoing data review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Related drug support groups
atorvastatin, Lipitor, simvastatin, Repatha, pravastatin, Crestor, Zetia, ezetimibe, rosuvastatin, Leqvio